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Objectives: To define and develop risk - and more specifically market access risk– 
as a framework towards understanding and evaluating stability in market access 
systems at an individual country level. MethOds: We created a combination model 
of rating quantitative and qualitative variables which affect a country’s ability and 
willingness to pay for new drugs. The criterion for selection of variables is based 
on relevance, availability and uniformity in our model. We included a total of 42 
variables categorised under three verticals - quantitative, qualitative and measures 
of stability. In order to derive a non-recursive model of ratings, we fit the regression 
equation for quantitative and qualitative variables as: Y(1) = α i + ∑β i*Xi + ε (Equation 
1.1) Y(2) = α j + ∑β j*Xj + ε (Equation 1.2) where Y(1) and Y(2) are the market access risk 
ratings for quantitative and qualitative variables, Xi and Xj are vectors of independ-
ent quantitative and qualitative variables, and ε is the error term. The final score 
was derived by taking the geometric mean of the two ratings together with ratings 
for the measures of stability and is described as below: Total Risk Score = √Y(1)^2* 
Weight of Y(1) + Y(2)^2*Weight of Y(2) + Risk Rating (Measures of Stability)^2*Weight 
of (Measures of Stability). Results: We decided to aggregate risk scores from dif-
ferent countries into defined clusters – such as BRICS (Brazil, Russia, India, China 
and South Africa), BRICS-MT (Brazil, Russia, India, China, South Africa, Mexico and 
Turkey), and Emerging Europe (Czech Republic, Hungary and Poland) - for easier 
comparison. Their respective risk scores were 4.17, 4.96 and 3.30. cOnclusiOns: 
Market Access Risk ratings could serve as a starting point for crafting tailored 
strategies to fully capitalise new opportunities. These ratings could also serve as a 
benchmark for a country to improve its overall access to pharmaceutical products 
and improve quality of care.
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Objectives: The process of disinvestment from inefficient health care involves 
identification and prioritisation of candidates, a health technology reassessment 
(HTR)of evidence, implementation and monitoring of discontinuance. We evalu-
ate whether variation in procedure rates is a useful tool for identifying potential 
candidates for HTR and disinvestment. MethOds: We used English Hospital 
Episode Statistics (HES) data to identify inpatient procedures. We selected the 181 
most frequent interventional procedures for analysis. For each procedure we used 
Poisson regression to estimate the variance in procedure rates, adjusting for age, 
gender and other proxies of clinical need, between Primary Care Trusts in England. 
We conducted multivariate regression analyses to examine factors that might be 
associated with high variation in procedure rates (e.g. coding uncertainty, evolving 
evidence). Results: The degree of inter-PCT variation in procedure rates differed 
vastly from procedure to procedure. Among the five procedures with the highest 
inter-PCT variance, the procedure rate was more than thirty times higher in the 
PCT at the ninetieth percentile than the PCT at the tenth percentile. The multivari-
able analysis provided strong evidence that large increases in procedure use, large 
decreases in procedure use, the presence of a substitute procedure, and shorter 
length of stay were all associated with higher inter-PCT variation in procedure 
rates. cOnclusiOns: The widespread geographic variation in hospital procedure 
rates in England are not solely due to variance in clinical need and are likely to 
reflect clinical uncertainty about appropriate procedure use which might be reduced 
by HTR. The relevant HTR questions often concern the appropriate procedure setting 
and patient subgroups or the relative value of two alternative procedures rather 
than the value of a single procedure per se. In some circumstances knowledge of 
geographic variation might lead to NHS savings and disinvestment or discontinu-
ation of inefficiently used procedures.
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Objectives: NICE has been issuing health technology guidance based on cost-
effectiveness evidence alongside other factors since 2000. Previous studies have 
shown that technologies with higher incremental cost-effectiveness ratio (ICER) 
were more likely to be rejected; however none drew direct inference on the ICER 
threshold(s). Our aim is to directly estimate the ICER threshold(s) as well as the 
possible range. MethOds: Data were abstracted from the technology apprais-
als (TA) published from 03/2000 to 12/2012. For each decision to ‘recommend’ 
or ‘reject’ a technology we collected: ICER, publish date, disease area, technol-
ogy type, comparator, reason for rejection if rejected, population and end of life 
(EOL) criteria (applies only to TAs after January 2009). Cancer related technolo-
gies which had been evaluated for EOL criteria were classified as satisfying or 
not satisfying the criteria. A Bayesian hierarchical model was implemented to 
estimate the overall threshold as well as the thresholds in different technology 
categories. Results: A total of 270 TA’s were evaluated. After excluding those 
updated or terminated, a total of 187 appraisals with 323 decisions entered the 
final analysis. Non-informative priors were given to all the model parameters. The 
unadjusted estimate of the ICER threshold was £46,850 (95% CI: £40,420-£55,570). 
After adjusting for disease area, cancer related technologies had an estimated 
threshold of £48,550, (95% CI: £36,550-£63,200) compared to non-cancer related 
technologies’ estimated threshold of £43,430, (95% CI: £35,440-£52,300). Among 
the 37 technologies evaluated for end of life criteria, the estimated ICER thresh-
old was £56,160, (95% CI: £39,020-£79,970) and £33,100, (95% CI: £19,180-£49,620) 
for those satisfying and not satisfying the criteria respectively. cOnclusiOns: 
Preliminary assessment of NICE appraisals and associated ICER indicates that a 
likely ICER threshold exceeds the £20K-£30K quoted in the NICE Methods Guide. 
Additional analyses are needed to assess the impact of other factors on the likely 
variability of ICER thresholds.
identify the PBAC’s main concerns relating to the methodology. MethOds: All PSDs 
published between July 2005 and November 2012 where the primary evidence was 
based on an indirect comparison, either as simple or a mixed treatment comparison, 
were reviewed. Data relating to comparator, clinical claim, economic analysis, and 
PBAC concerns were extracted and analysed. Results: PSDs relating to 105 products 
using an indirect comparison as the primary analysis were reviewed. A total of 70 
(67%) submissions were recommended; the remaining submissions were rejected (32, 
30%) or deferred (3, 3%). An indirect comparison was used to support a non-inferiority 
claim in 84 (80%) submissions and superiority claim in 21 (20%) submissions. Of those 
claiming non-inferiority, 60 (71%) submissions were recommended by the PBAC. Of 
those claiming superiority, the PBAC accepted the clinical claim for 10 (48%) submis-
sions; 6 (29%) received a price premium. The PBAC expressed concerns relating to the 
indirect comparisons in 56 (53%) PSDs. The key issues related to the exchangeability 
of the trials as a consequence of different patient populations (25%), quality of tri-
als (24%), and dosing (18%). cOnclusiOns: Clinical comparisons based on indirect 
evidence are associated with increased uncertainty related to the exchangeability of 
the trials. The PBAC usually accepts evidence to support a claim of non–inferiority, 
but rarely the same in regards to superiority.
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Objectives: Since 2010, cost contaiment efforts in Greece focused on the reduction 
of public pharmaceutical expenditure. Changes in cost sharing levels (dementia/alz-
heimer & epilepsy 0%-10%, osteoporosis & copd: 10-25% etc.), reductions in prices and 
generics substitution are some of the measures implemented after the second quar-
ter of 2012. The aim of the study is to investigate the economic impact of the above 
measures for public funds and households. MethOds: Data on volume and values 
for prescribed drugs for each therapeutic category and cost sharing level were derived 
from EOPYY, the main reimbursement agency (95% of population). The periods com-
pared were January to February 2012 vs. January to February 2013. Results: During 
2009-2011, public pharmaceutical expenditure in Greece declined by 23%, while for 
2009-2014 the decline is projected at 61%.During 2013, 2014 targets are € 2.44billion or 
1.3% of GDP and 1.935 billion or 1% of GDP. In 2013, only 8.2% of prescribed drugs boxes 
were provided free of charge, vs 13.6% in 2012 A 25% cost sharing level was imposed 
to 76.4% of prescribed medicines in 2013 compared to 51.4% in 2012. Consequently, 
the mean cost-sharing burden for pharmaceuticals in 2013 was estimated at 18% vs 
13.1% in 2012. Monthly savings in public expenditures from changes of cost–sharing 
patterns was estimated at € 18-€ 20 mil. Average price per package declined in 2013 
by 23%, from € 18 in 2012 to € 14 in 2013. Public funds savings, because of consump-
tion of cheaper drugs, were estimated at € 55-€ 60 mil.per month. Major savings for 
public funds were achieved through cardiovascular diseases drugs cOnclusiOns: 
The economic results of the measures for third party payers are positive. However, 
the measures should be reconsidered and examined more closely also taking in mind 
social effects, in terms of accessibility of users and especially for vulnerable groups 
who in need of essential pharmaceutical care.
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Objectives: Under the pressure of fiscal consolidation and pharmaceutical spending 
decrease in Greece, mandatory generic substitution and compulsory prescription by 
international non-proprietary name (INN)were recently introduced as reimbursement 
drivers in Greece. This study aims to investigate the implications of INN implementa-
tion regarding chronic patients’ choices and their willingness to switch to an alter-
native pharmaceutical treatment. MethOds: A cross-sectional study was carried 
out among 1600 patients from four chronic disease groups(HTN, Diabetes,COPD and 
Alzheimer). Logistic regression analysis was used to investigate the factors asso-
ciated with chronic patients’ choices. Results: Out of 1600 patients approached, 
1594responded to the survey(99.6%). 69% of them stated that they were aware of 
the new reimbursement system. After the implementation of INN prescribing, only 
few(11%) have changed their usual drug. 43% were totally certain that an original 
drug is more effective than a generic, while 67% have never used generics in the 
past. Most patients(82%) preferred to be prescribed their usual medicine, despite of 
the extra cost they had to bear. This choice was a co-decision with their physician 
as 58% of them stated. The average additional amount that they would be willing to 
spend in order not to switch to another medicine was estimated at € 17.8. These results 
showed a significant statistical correlation with patients’ income, educational level 
and occupation category. cOnclusiOns: According to this study chronic patients 
are not willing to change their usual drug and switch to a generic, despite the cost 
this choice imposes. Consequently INN prescribing may decrease public expenditures 
on pharmaceuticals but it will lead to higher private expenditure. Given that due to 
economic crisis incomes are continuously decreasing and unemployment rate is 
rising, the measure might eventually result in lower adherence to medication and 
consequently in adverse effects on patients health status and future public expendi-
ture for treating possible complications.
PHP101
market aCCess risk sCoring: a unified framework for Cross Country 
ComParison of diVerse market aCCess systems and ProCesses
Mehta P., Ando G.
IHS, London, UK
